Want to see AU:IMR full AI Analyst Report?
Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$1.50
▼(-21.87% Downside)
Action:Reiterated
Date:07/03/26
Overall score is held down primarily by weak financial performance: very small and declining revenue, structurally negative gross profit, large net losses, and significant ongoing cash burn alongside higher leverage. Technicals provide meaningful offset with the stock trading above key moving averages and positive momentum indicators. Valuation remains a modest negative due to loss-making status (negative P/E) and no dividend yield support.
Positive Factors
Specialized MRI-guided electrophysiology platform
The company operates in a specialized medical-device niche linking electrophysiology with real-time MRI guidance. This focused platform may support durable differentiation as hospitals develop MRI-enabled cardiac procedure capabilities.
Negative Factors
Sharp revenue contraction
Very small and declining revenue indicates that product adoption and procedure utilization have not yet reached a commercially sustainable scale. Continued contraction would limit operating leverage and make fixed costs increasingly difficult to absorb.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized MRI-guided electrophysiology platform
The company operates in a specialized medical-device niche linking electrophysiology with real-time MRI guidance. This focused platform may support durable differentiation as hospitals develop MRI-enabled cardiac procedure capabilities.
Read all positive factors
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$702.80M
Dividend YieldN/A
Average Volume (3M)412.13K
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue Growth-68.64%
EPS Growth36.40%
CountryAU
Employees78
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.11
Shares Outstanding358,572,500
10 Day Avg. Volume264,052
30 Day Avg. Volume412,128
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.98Price Target Upside55.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$2.68M
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Company Description
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East....
How the Company Makes Money
null...
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 121.83K | 302.50K | 959.42K | 615.57K | 816.01K | 696.27K |
| Gross Profit | -2.81M | -2.10M | -924.12K | -1.12M | -1.53M | -1.90M |
| EBITDA | -26.75M | -22.56M | -15.55M | -21.87M | -16.47M | -19.57M |
| Net Income | -37.54M | -26.20M | -29.69M | -22.63M | -17.53M | -20.56M |
Balance Sheet | ||||||
| Total Assets | 73.59M | 45.79M | 21.62M | 8.31M | 13.70M | 26.86M |
| Cash, Cash Equivalents and Short-Term Investments | 67.46M | 40.81M | 15.71M | 831.52K | 5.69M | 18.52M |
| Total Debt | 34.02M | 25.97M | 21.35M | 10.42M | 4.45M | 1.74M |
| Total Liabilities | 44.52M | 34.26M | 29.00M | 17.06M | 6.19M | 4.46M |
| Stockholders Equity | 29.07M | 11.53M | -7.38M | -12.83M | 7.51M | 22.40M |
Cash Flow | ||||||
| Free Cash Flow | -24.67M | -20.20M | -15.65M | -13.06M | -17.06M | -18.11M |
| Operating Cash Flow | -23.87M | -19.75M | -15.57M | -12.98M | -16.82M | -17.49M |
| Investing Cash Flow | -8.11M | -22.47M | -74.98K | -82.78K | -238.86K | -695.30K |
| Financing Cash Flow | 40.39M | 44.55M | 30.33M | 8.21M | 3.94M | 11.59M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Positive
1.92
Price Trends
1.90
Positive
1.87
Positive
1.83
Positive
Market Momentum
<0.01
Positive
52.17
Neutral
34.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Positive. The current price of 1.92 is below the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.90, and above the 200-day MA of 1.83, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 34.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMR.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | AU$702.80M | -12.32 | -184.93% | ― | -68.64% | 36.40% | |
50 Neutral | AU$174.76M | -20.59 | -46.84% | ― | ― | 20.40% | |
45 Neutral | AU$20.14M | -0.43 | -259.31% | ― | 14.85% | -1.74% | |
45 Neutral | AU$42.87M | -12.12 | -198.77% | ― | -52.35% | 40.38% | |
41 Neutral | AU$65.38M | -3.25 | -62.14% | 0.64% | 12.05% | -31.71% | |
37 Underperform | AU$16.55M | -1.54 | -188.06% | ― | 15.58% | 37.17% |
* General Sector Average
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.96
0.60
43.59%
AU:IPD
Impedimed Limited
0.01
-0.03
-65.00%
AU:HMD
HeraMED Ltd.
0.04
0.00
0.00%
AU:CYC
Cyclopharm Limited
0.52
-0.36
-40.91%
AU:MX1
Micro-X Ltd.
0.02
-0.07
-75.56%
AU:EMV
EMvision Medical Devices Ltd.
1.88
-0.10
-5.05%
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Adds Children’s Medical Center Dallas as Second U.S. NorthStar Customer
Aug 9, 2026
Imricor Medical Systems has secured Children’s Medical Center Dallas as its second U.S. hospital customer for the NorthStar interventional magnetic resonance mapping and guidance system, just two weeks after its domestic commercial launch. T...
Imricor outlines regulatory framework and limits of new 1H 2026 investor briefing
Aug 9, 2026
Imricor Medical Systems has released a 1H 2026 investor presentation outlining general background information on the company, its activities, and its securities on the ASX. The document emphasises that the materials are a high-level summary, rely ...
Imricor Files Q2 2026 10-Q, Confirms Status as Emerging Growth Medical Tech Company
Aug 9, 2026
Imricor Medical Systems, Inc. has filed its quarterly report on Form 10-Q for the period ended June 30, 2026, confirming it remains a non-accelerated, smaller reporting, emerging growth company under U.S. securities regulations. The company report...
Imricor accelerates U.S. MR-guided cardiac launch with Rady Children’s and fresh capital
Aug 9, 2026
Imricor has formally entered the U.S. market, launching its Imricor Cardiovascular business line and securing Rady Children’s Hospital–San Diego as its first American customer for the NorthStar-guided, radiation-free cardiac catheteris...
Imricor Gains Philips Compatibility, Expands iMR Footprint Ahead of ESC Congress
Aug 6, 2026
Imricor Medical Systems has secured a Third Party Product Compatibility Declaration from Philips Medical Systems covering its interventional MR products for use with specified Philips MR systems and upgrades running R12.1.1 or later. The certifica...
Imricor sets date for Q2 FY26 results and investor webinar
Aug 3, 2026
Imricor Medical Systems will release its financial results for the quarter ended 30 June 2026 on 10 August 2026 and will host an investor webinar the same morning, led by Chair and CEO Steve Wedan and CFO Jonathon Gut. The event underscores the co...
Imricor launches U.S. operations with MR-guided cardiac program at Rady Children’s
Jul 26, 2026
Imricor has commenced its official U.S. commercial launch with Rady Children’s Hospital–San Diego becoming the first commercial U.S. customer for its NorthStar iMR mapping and guidance system. Rady Children’s will pioneer radiati...
Imricor Issues 270,000 Unquoted Options Under Employee Incentive Plan
Jul 14, 2026
Imricor Medical Systems, Inc. has notified the market of the issue of 270,000 unquoted options under its ASX security code IMRAJ, with varying expiry dates and exercise prices. These options have been granted under an employee incentive scheme and...
Imricor Issues New CDIs on Option Exercise and Reaffirms Compliance, Ownership Limits
Jul 13, 2026
Imricor Medical Systems has issued 5,051,539 CHESS Depositary Interests at A$0.61 each upon the exercise of existing options, with the new securities ranking equally with its existing CDIs and Class A common stock. The company has confirmed compli...
Imricor seeks ASX quotation for over 5 million new CDIs
Jul 13, 2026
Imricor Medical Systems Inc. has lodged a new Appendix 2A application with the ASX to quote 5,051,539 CHESS Depository Interests on 13 July 2026. The new securities, described as CDI 1:1 with U.S. person restrictions, expand the company’s qu...
Imricor Wins FDA Nod for MR-Guided Pediatric Cardiac Devices in U.S.
Jul 1, 2026
Imricor Medical Systems has secured U.S. FDA 510(k) clearances to expand the labeling of its NorthStar MR-native 3D mapping system and Vision-MR Diagnostic Catheter for use in pediatric patients. The move broadens the eligible patient population t...
Imricor Registers Shares for Equity Incentive Plan with U.S. SEC
Jun 25, 2026
Imricor Medical Systems, Inc., a specialist in MR-guided cardiac ablation technologies, has filed a registration statement on Form S-8 with the U.S. Securities and Exchange Commission to register 38,877,464 shares of Class A common stock. These sh...
Imricor Wins ASX Waiver as U.S. Reporting Status Takes Effect
May 26, 2026
Imricor Medical Systems, Inc., a U.S.-based medical technology firm listed on the ASX, now reports as a U.S. public company under the Securities Exchange Act of 1934. The company must file annual reports on Form 10-K and quarterly reports on Form ...
Imricor Options Lapse, Trimming Potential Future Dilution
May 21, 2026
Imricor Medical Systems has notified the market that 30,000 IMRAJ options, which were exercisable at various prices and expiring on various dates, have lapsed unexercised as of 13 May 2026. The expiry of these options, disclosed in an Appendix 3H ...
Imricor Corrects Executive Equity Allotment in ASX Filing
May 21, 2026
Imricor Medical Systems, Inc. has updated its disclosure to correct a typographical error in the reported number of unquoted securities issued to key management personnel. The company clarified that executive Jonathon Gut received 231,656 securiti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.